Does He Not Realize… Ari Onassis Heard Much The Same?! Sheesh!

~ condor ~ Leave a comment

Well, it seems Mr. Trump can’t understand that — in the case of many wealthy older men who’ve had multiple wives, and are presently with younger wives — a common joke for decades from comedians has been that the younger wife has been invested in / involved… with… waiting for them to die. Just ask Andrew Dice Clay, Rodney Dangerfield, and before them, Lenny Bruce.

We may quibble about whether that particular joke was in good taste — given what happened later in the evening, Saturday night. But there is no doubt that Mr. Kimmel’s joke is protected expression.

So I will rerun my column from November 2025 and the last time Donald Trump tried to punish speakers (including comedians!) whose jokes offend him — and of whose views he does not approve:

Tangerine and Melania today said it pretty plainly, that FCC should review (with a threat toward revoking) the broadcast licenses of networks that criticize him.

Charming. We will — as ever — peacefully — resist. Resist the trampling of our First Amendment rights.

Nearly 250 years of freedom now hang in the balance. Forget this loser, folks:

…President Trump said federal regulators should revoke broadcast licenses over late-night hosts who speak negatively about him, a day after ABC pulled Jimmy Kimmel’s show “indefinitely” after pressure from the Federal Communications Commission chairman….

“They’re giving me all this bad press, and they’re getting a license,” Mr. Trump told reporters aboard Air Force One, after ABC suspended the late-night Jimmy Kimmel Live show. “I would think maybe their license should be taken away….”

Not on my watch you Manchurian Cantaloupe.

Nope. And Hinderaker is very pissy about it, but I don’t care. I refuse to link his nonsense.

नमस्ते

New Data Out Of US CDC Suggests That Mpox Clade 1b Is Unlikely To Be A Vector, On The Summer’s Commercial Air Travel Routes: CIDRAP

~ condor ~ Leave a comment

Of course, the Clade 1b is associated with the more severe symptoms — and is thus of highest concern. But the empirical data so far suggests the data of “catching it” — from an infected seat mate, on a jet… is negligible. That’s good news, as so many will hop on international flights — from as early as June through November of this year, here.

Still — there are reports of people with Clade 2, getting sick on the airplane. So far, none of those have resulted in “close contact” transmission, to others on the plane. But if you’ve had, or have Clade 2, please do not board a plane until you are virus free (no visible legions). In any event, here’s the pretty reassuring news — from the U of Minn’s fine CIDRAP outlet:

…Transmission of clade 1 mpox virus during commercial air travel appears to be uncommon, according to a study published yesterday in Morbidity and Mortality Weekly Report from the US Centers for Disease Control and Prevention (CDC).

The analysis looked at data from five commercial flights taken by three men with active mpox symptoms to assess the risk of in-flight transmission. The three men were aged 20 to 40 years. The flights took place from November 2024 to January 2025.

Among 60 identified contacts, defined as nearby passengers and crew, one person reported symptoms of fatigue, body aches, and a skin lesion after the flight, but that person tested negative for mpox. No secondary cases were identified….

Based on these results, the CDC discontinued routine aircraft contact tracing for all mpox clades and subclades in 2025. But public health officials continue to recommend that people with mpox avoid travel until they have fully recovered. Vaccination of at-risk groups remains an important tool for reducing transmission and disease severity, the authors said….

Onward, to “remote view” the 2026 Eugene Marathon tomorrow, over the web/on the internet — and track my youngest’s progress in getting down to world class splits. Smile….

नमस्ते

DC Appeals Court Rules (AGAIN!) Trump Pretended To Have Power Over Asylum Seekers… He Plainly Lacked. End Of Tangerine Proclamation 10888.

~ condor ~ Leave a comment

A per curiam opinion — out of the DC federal Court of Appeals today tells us all what we long knew: Trump cannot countermand Congressionally mandated due process, for people who seek protection from abuse at our borders — no matter where they cross.

Once again, his black Sharpie scribbles mean… essentially nothing, not without an entirely new act of the Congress. And that never happened. At all.

So he is (again) toast — and people seeking asylum in the US must be granted due process hearings, despite what the dotard says — here’s that 105 pager, and a bit of the opening stanzas:

…More than a century of precedent assures that “over no conceivable subject is the legislative power of Congress more complete” than it is over the admission of foreign individuals. Dep’t of State v. Muñoz, 602 U.S. 899, 903 (2024) (quoting Oceanic Steam Navigation Co. v. Stranahan, 214 U.S. 320, 339 (1909)); see also INS v. Chadha, 462 U.S. 919, 940 (1983) (“The plenary authority of Congress over aliens under Art. I, § 8, cl. 4 is not open to question.”)….

This is a statutory interpretation case. Our task is to determine whether Congress has granted the Executive the authority to remove foreign individuals present in the United States without adhering to the removal procedures or providing the substantive removal protections that Congress prescribed in the INA….

We conclude that the INA’s text, structure, and history make clear that in supplying power to suspend entry by Presidential proclamation, Congress did not intend to grant the Executive the expansive removal authority it asserts.

The Proclamation and Guidance are thus unlawful to the extent that they circumvent the INA’s removal procedures and cast aside federal laws affording individuals the right to apply and be considered for asylum or withholding of removal protections. Accordingly, we affirm the district court’s grant of summary judgment in favor of Plaintiffs. We also affirm the district court’s class certification order, modifying the class definition as clarified by this opinion….

Yep — bit by bit, sanity (and the rule of actual law) is making a come-back. Onward, resolutely.

नमस्ते

Tangent: A Trend Line, On Tesla / Muskian Lobby Spend, Since Tangerine 2.0 Began…

~ condor ~ Leave a comment

[As long as we are digging through crates of federal forms, this morning… “why not?” Right? Right.] This is what his spend trend looks like, at right.

And this is the first time we’ve ever detailed how he went down the (at least on legal/on-the-record) path — of lobbying Tangerine 2.0. Obviously, his role in the early days of Tangerine 2.0 were chaotic.

Issues related to avoiding any meaningful oversight — and preserving federal EV tax breaks, probably predominated. That, and getting him “in” at DOGE, while never filing a conflict of interest disclosure form required by federal law, nor disclosing his finances, in full — thus effectively avoiding all Congressional oversight efforts… was the whole game. Then, he bailed before the LDA authorities could act, to bring him in for a chin-waggle. Damn.

In any event, here’s the latest (small by pharma standards, but he has his fingers in lots of different pots, to be certain — including national defense, via SpaceX contracts). I suppose it is mostly surprising… how cheaply the MAGA-Congress-critters may be bought:

…Autonomous Vehicle policies; Artificial Intelligence/Robotics; Surface Transportation Reauthorization; EV Fees/Highway Trust Fund Reform; EV charging infrastructure/EV signage; National Electric Vehicle Initiative (NEVI); Advanced Battery Supply Chain and Manufacturing; Automotive Technology and Safety; Privacy; H.R.1566, REPAIR Act; SELF DRIVE Act….

H.R.1, One Big Beautiful Bill Act; Critical Minerals and Battery Components….

General trade policies; Issues related to manufacturing supply chain; Issues related to non-tariff trade barriers; Issues related to global market access and global competitiveness….

Solar and energy permitting; Virtual Power Plants; Energy Storage….

Permitting and critical mineral policies; Permitting Reform provisions related to Budget Reconciliation; Discussions regarding export controls….

Issues related to transportation appropriations, Issues related to H.R.1, One Big Beautiful Bill Act, permitting reform, Highway Trust Fund, NEVI/CFI, and Spectrum Auction Authorities….

Issues related to spectrum/ultra-wide band….

Issues related to Significant New Alternatives Policy Program; Issues related to TSCA….

Issues related to intellectual property….

[SpaceX:] The FY2027 National Defense Authorization Act (No Bill Number): issues related to space launch competition….

The FY2027 National Aeronautics and Space Administration Authorization Act (No Bill Number): issues related to commercial, civil, and defense space transportation. General monitoring of issues related to the space launch licensing approval process….

The FY2027 Defense Appropriations Act (No Bill Number): issues related to the funding of military space launches. The FY2027 Commerce, Justice, Science, and Related Agencies Appropriations Act (No Bill Number): issues related to the funding of civil and military space launches….

As I say, this whole thing… smells. Smells to high heaven. And we all know (in our heart of hearts) much, much more moved, via dark money — but this is just the tiny portion required to see… sunshine, under long-standing federal laws.

D A M N A T I O N.

Elon — being Elon. And MAGA cheering it on.

नमस्ते

Now Pfizer’s Q1 ‘26 Spend: Pretty Much Steady State, Compared To Q1 ‘25

~ condor ~ Leave a comment

This is number three of a four part series — maybe five — if I decide to add in either Tesla (for Elon, here) — or Amazon Health. For now, this is what the largest spend of the majors went to in Q1 2026.

You’ll notice that — unlike the others, Pfizer goes into far less detail about exactly what they are jaw-boning about. It is my opinion (expressed here, on and off for about 15 years) that, given how relatively high the company’s spend on lobbying is every year — that this below, barely meets the command of the statute, to describe, in reaonable detail, “a list of the specific issues upon which a lobbyist employed by the registrant engaged in lobbying activities, including, to the maximum extent practicable, a list of bill numbers and references to specific executive branch actions…” at 2 USC § 1604 Section (b)(2)(A):

…[US House] Vaccine Coverage; Pediatric Immunization Schedule; Vaccine Injury Compensation Program; Executive Order 14297 – Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients; H.R. 7837 – Most Favored Patient Act of 2026; Lyme Disease Issues; 340B Issues; Counterfeit Drugs; Inflation Reduction Act (IRA); Prescription Drug User Fee Act (PDUFA); Drug Pricing; PBM Reform; Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage; H.R. 5509 – Safe Step Act; S. 2903 – Safe Step Act; S. 3510 – Biosimilar Inspection Modernization Act of 2025….

[US Senate] Executive Order 14297 – Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients; Prescription Drug User Fee Act (PDUFA); 340B Issues; Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage; PBM Reform; Counterfeit Drugs; P.L. 117-169 – Inflation Reduction Act (IRA) of 2022; Drug Pricing; Medicare/Medicaid Issues….

International Supply Chain; Market Access; Most Favored Nation Policies; Foreign Freeriding Issues; Non-Tariff Trade Barriers; Competiveness Issues; Trade Issues….

Intellectual Property Protections….

Onward, to a warm if cloudy Spring Friday morning — Eli Lilly likely up next, before Noon. Smile… maybe old Elon next, as he takes SpaceX public.

नमस्ते

In Which Hinderaker… Earns His White Hood & Sheet/Robes — Anew.

~ condor ~ 3 Comments

Of course, he had to come forward — with the most preposterous of lies, since more likely than not, he helped engineer this bogus indictment in the first place through his MAGA contacts in the “justice department”.

I won’t repeat a word of what Hinderaker said. It. Is. All. Lies.

But I will note that the resurgence of the Klan was a direct response — to the election of Barack Obama in 2008.

Hinderaker’s false timeline, even in his own argument — is full of holes, lies and misrepresentations. There had been documented resurgent Klan gatherings and activity throughout the last half of the 1990s (as Bill Clinton advanced various civil rights measures), and they mostly subsided, while Bush43 was president. [Mostly because these hate groups were getting their way.]

All the while, the Southern Poverty Law Center was investigating, and yes, using paid informants (who were risking their very lives), to keep track of Klansmen — nationwide. [This is in no manner like Steve Bannon essentially stealing charity funds, from “We Build The Wall” — to pay off his personal credit card debts, rent wild private jet rides, and fund his other hate enterprises.]

As just one example, consider that Matthew Hale, and the World Church of the Creator hate group, were first identified by the SPLC, shortly after Ricky Birdsong was murdered in cold blood (in a racial assassination) not even one and a quarter miles from my house.

He was shot dead — in front of his daughter — while they were jogging. He was also the head basketball coach of Northwestern University.

Quickly finding his killers (and their affiliations to whyte supremacy / evil insanity groups), was in part due to the efforts of the SPLC — and that organization’s databases. Notice that that is at least 15 years prior to the idiotic claims in Hinderaker’s timeline.

What an embittered, darkly shriveled and decrepit soul that John is.

Out.

The Able USDC Judge Xinis Will Hold A Very Illuminating Hearing In Maryland, On May 12, 2026 — But I’lll Be In The High Rockies, Then.

~ condor ~ Leave a comment

Mr. Abrego Garcia — and his counsel — have all of this nonsense well in hand. They will win, on May 12, 2026.

I’ll not likely even try to get cell-service, to listen in on that day. And by then, the Fourth Circuit is likely to have summarily dismissed Todd Blanche’s rather… insane “appeal” — in any event:

…PAPERLESS ORDER

In light of Petitioner’s motion at ECF 166 [Ed. Note: 166 is a motion from Abrego’s counsel, for an indicative ruling that the government’s pretending to have a final order of denial — which Judge Xinis has never intimated, let alone entered — upon which to base its immediate appeal, to the Fourth Circuit — an appeal Todd Blanche filed anyway (without even a shred of authority for)!] and in the interest of fairness and judicial economy, the Court hereby

RESCHEDULES the in-person hearing to May 12, 2026 at 11:00AM [EDT] in Courtroom 2C, and sets the following briefing schedule:

Respondents SHALL respond to the motion at ECF [166] by April 28, 2026;

Petitioner SHALL reply by May 5, 2026.

Signed by Judge Paula Xinis on 4/22/2026….

Now you know. Onward, resolutely, against this lawless thuggery.

नमस्ते

And Here Is The Significantly DECREASED Amgen Spend — And Where All It Went, In Q1 2026…

~ condor ~ Leave a comment

As I indicated in the last post, it seems Merck has increased its spend by almost as much as Amgen has cut its. Interesting — we shall see if this reversal of fortunes continues through all of 2026. [It is typical that all majors may decrease spending slightly, in the third quarter, as Congress may recess for most of August.] So, we shall wait and see what Q2 brings.

Here is the decreased Amgen Q1 2026 — and you may compare it to the Amgen Q1 2025 listing, here, in any event:

…[Both Houses of Congress:] Issues related to drug pricing; Issues related to cardiovascular disease awareness and treatment; Issues related to FDA; Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters; Issues related to biosimilars reimbursement; Issues related to Supply Chain; Issues related to 340B; Issues related to pharmacy benefit managers; Issues related to biosimilars regulatory standards; Issues related to bone disease awareness and treatment; Issues related to Public law 117-1769 Inflation Reduction Act; HR 1492 Ensuring Pathways to Innovative Cures Act; HR 1672 Maintaining Investments in New Innovation Act; HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14); S 1954 Biosimilar Red Tape Elimination Act; S.3345 PBM Price Transparency and Accountability Act; H.R. 6166 Lowering Drug Costs for American Families Act; S.3019 No Big Blockbuster Bailouts Act; HR 4317 PBM Reform Act; S 3510 Biosimilar Inspection Modernization Act; PL 119-75 Consolidated Appropriations Act of 2026; HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act; H.R.7837 Most Favored Patient Act of 2026; S 3788 Clear Labels Act; HR 5256 340B Access Act; H.R.5526 Biosimilar Red Tape Elimination Act; HR 7391 Community Health Center Drug Pricing Protection Act….

Issues related to drug pricing; Issues related to cardiovascular disease awareness and treatment; Issues related to reimbursement for biologics/biosimilars; Issues related to PBM reform; Issues related to bone disease awareness and treatment; HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14); S.3345, PBM Price Transparency and Accountability Act; HR 6166, Lowering Drug Costs for American Families Act; S 3019 – No Big Blockbuster Bailouts Act; S 3349 PBM Disclosure Act; HR 4317 PBM Reform Act; Issues related to Public law 117-1769 Inflation Reduction Act; HR 1492 Ensuring Pathways to Innovative Cures Act (EPIC); HR 1672 Maintaining Investments in New Innovation Act (MINI); HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act; H.R.7837 Most Favored Patient Act of 2026; PL 119-75 Consolidated Appropriations Act of 2026….

[Taxes:] Issues related to corporate and international tax; Public Law 115-97, Tax Cuts and Jobs Act; Public Law 119-21, One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14); Issues related to Puerto Rico; Issues related to OECD negotiations on the taxation of global income….

Federal Trade Commission related issues: Issues related to the Patent Act, no specific bill; Issues related to March-In/Bayh Dole, WTO/TRIPS; Issues related to patent thickets; Issues related to obviousness/ double patenting; Issues related to FDA/PTO coordination; Issues related to skinny labeling; S.1041 A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes; S.1040 -A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes; S 708/ HR 1574 — Realizing Engineering, Science and Technology Opportunities by Restoring Exclusive Patent Rights Act of 2025 (RESTORE); S.1553/HR3160– Promoting and Respecting Economically Viable American Innovation Act (PREVAIL); S. 1546/ HR 3152– Patent Eligibility Restoration Act of 2025 (PERA); S 2276 / HR 3269 Eliminating Thickets to Increase Competition Act (ETHIC Act); S. 43/HR 6485 Skinny Labels Big Savings Act; S.2658 Medication Affordability and Patent Integrity Act; S. 3452/HR 6624 Biological Intellectual Property Protection Act of 2025….

Issues related to tariffs; Issues related to trade agreements; S. 3452/HR 6624 Biological Intellectual Property Protection Act of 2025….

Now you know — and maybe, just maybe — Amgen figured out that the Supremes (as we’s long said — and as did many other wise heads) were going to all but end tariffs regardless, and thus the company needed to spend less overall, in Q1 — jaw-boning Congress for some future possible legislative “fix“.

Who knows? Anyhoo — onward now, grinning into the Spring sunshine, for a bike ride — by the clear, cold azure waters of the lake….

नमस्ते

Merck’s Q1 Lobby Spending Is Almost Double Last Year’s Q1, And Nearly Above [Gargantuan] Pfizer’s — From Last Year’s Q1…

~ condor ~ Leave a comment

This is, admittedly, a complete surprise. To be fair, Pfizer will likely always be about 30% bigger than Merck, on NYSE market cap and asset base — and thus, lobby spending.

But this huge jump in Q1 2026, for Merck seems… out of character, over the past seven or so annual cycles. [In the next in this series, we will add in the Amgen spend, which has fallen by almost as much as Merck’s has… risen. Odd.]

Why now? Why so much — in each direction?! We are abidingly curious — especially compared to the peer group. In any event, see my chart at right, and the below, filed on April 20 [and look for a four way version, with Amgen in, tonight or tomorrow]:

…[Senate] S. 1339, Pharmacy Benefit Manager Reform Act; S. 2076, Pioneering Antimicrobial Subscriptions To End Upsurging Resistance (PASTEUR) Act of 2021….

Issues relating to: 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Cost and value of medicines; Vaccine issues; Package inserts and e-labeling; Package inserts, labeling issues, and e-labeling authorization legislation; Pharmaceutical supply channel issues; Drug shortages issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; One Big Beautiful Bill Act (P.L. 119-21), issues related to health care; FY-2027 Budget and Appropriations Legislation; Budget reconciliation drug pricing provisions; Commerce Justice, Science, and related agencies appropriations legislation for 2026; Interior, Environment, and related agencies appropriations legislation for 2026; Intellectual property protection and trade issues; Animal Health Policy Issues; Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Vaccine Policy; Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms; Food and Drug Administration issues; Public Health Issues; Most Favored Nation (MFN) drug pricing; Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients; International competition in biopharmaceuticals….

[US House] Issues relating to: One Big Beautiful Bill Act (P.L. 119-21), issues related to health care; Medicare; Medicare Part B and D drug pricing issues; 340B program integrity; 340B of the Public Health Services Act; 340B drug pricing program; Drug pricing; Cost and value of medicines; Drug pricing and reimbursement issues; FY-2027 Budget and Appropriations Legislation; Medicaid drug rebate program (MDRP)….

[Taxes] Issues relating to: Tax reform and tax policy, generally; Inflation Reduction Act (P.L. 117-169), provisions relating to budget reconciliation and taxes; Tax Cuts and Jobs Act (P.L. 115-97), provisions relating to tax reform….

[Animal Health] Issues relating to: Animal Health Policy Issues; Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; Agriculture, Rural Development , Food and Drug Administration, and Related Agencies Appropriations Bill, 2026; Commerce, Justice, Science, and Related Agencies Appropriations Bill, 2026; Interior, Environment, and Related Agencies Appropriations Bill 2026….

That is — overall, a rather stunning reversal in spend levels. Mr. Davis must believe that the arms of the federal government may be bent / bought, with enough… lucre. Wow — under Trump, that might be true. Onward.

नमस्ते

Who’ Da’ Thunk It?! A Career-Grifter Grifts Some Other Career-Grifters… And Now Says (In A Federal Suit)… They “Defrauded” Him. Shocking. Not.

~ condor ~ Leave a comment

Really. This couldn’t possibly happen to. . . a nicer bunch of people — on both sides.

You may recall, that during Trump 1.0, Justin Sun paid $4.6 million — in an online charity auction — just to have a one hour lunch with Warren Buffett, in Omaha. Mr. Sun hoped to convince Mr. Buffett that crypto- was not “rat poison, squared“. He failed.

Mr. Sun was then sued in 2023, by the SEC — on allegations of fraud, wash-trading, and illegal promotion of crypto assets (Tronix and BitTorrent). Those charges were settled for a small sum, at the SEC, within this past 12 months, under Trump 2.0 — after Sun had “invested” ~$45 million in WLFI, a Trump family-affiliated (purported) crypto- multi-platform.

Then the people at WLFI locked up his “investment” — preventing him from being able to sell it — or so he claims. WLFI is likely to say they’ve locked everyone — into their “positions” — and no one can sell. The question is… what did the contracts allow / prohibit? [The full and fair disclosures of SEC rules (free of material omissions) arguably do not govern these crypto- investing contracts — it is caveat emptor, or so the MAGA-administration asserts.]

Mr. Sun says he was promised liquidity, and in short order. That plainly has not happened [but does he have that promise in writing?]. Thus the 52 page fraud suit, in California’s northern federal District courts:

…World Liberty repeatedly claimed its mission was to promote the “liberty” provided by DeFi, summed up in the gold paper as “the ability to transact privately and without intermediaries.” The gold paper decried the “centralized control” of “traditional financial intermediaries,” lauded the “freedoms that decentralized assets provide” and the benefits of “peer-to-peer systems of transactions,” and pledged to make DeFi “readily available to mainstream Americans.” To those ends, the gold paper announced World Liberty’s plan “to launch the World Liberty Financial Protocol (‘WLF Protocol’), a US-based decentralized platform, that is intended to offer users with information about and access to certain third party DeFi applications, based on American ideals of liberty, privacy, and freedom to transact.” The gold paper thus boasted that World Liberty was “intended to be more than a decentralized finance platform” and was “committed to democratizing access to DeFi and fostering mass adoption of DeFi and cryptocurrency….”

As part of World Liberty’s professed goal to “to democratize finance,” the gold paper explained, “$WLFI tokens represent a right to vote on certain WLF Protocol matters.” According to the gold paper, token holders could “submit proposals[,] discuss them and vote on WLF Protocol changes, marketing initiatives, new features, and more.” Indeed, the gold paper noted that World Liberty was “required in its bylaws to defer to certain token holder votes.” The gold paper further stated that the “WLF Governance Platform is community-governed through the $WLFI token” and that “World Liberty Financial governance is divided into two categories of votes,” the first of which was “[a]pproved upgrades to the WLF Protocol.” The gold paper thus described $WLFI as “the governance token at the heart of World Liberty.” In fact, the gold paper claimed that because $WLFI tokens were initially locked from trading and conferred “no right of return or other distribution,” the “sole utility of holding $WLFI is governance of the WLF Protocol….”

Pop the popcorn, folks. And me? I’m waiting for Mr. Sun to say under oath, in a deposition, that he feels he did not get the full value of “the bribe” he agreed to pay — and did pay. . . to Trump, and his minions. Stay tuned. Grin.

नमस्ते